Back to Agenda
[V2-S1] Changes Required for Risk Minimization Materials
Session Chair(s)
Mamoru Narukawa, PhD, RPh
Professor
Kitasato University, Japan
It has been 5 years since the RMP was implemented in Japan. The risk minimization measure, which is vital in considering the RMP as well as the Benefit Risk balance, is becoming more important. With regard to materials for healthcare professionals and for patients which have been part of the risk minimization measure in Japan, this session will discuss the direction of changes required in the future, based on current issues.
Speaker(s)
Points to Consider for Implementation of Risk Minimization Materials
Kazuhiko Ishida, MSc, RPh
Astellas Pharma Inc., Japan
Director, Pharmacovigilance
Recognition and Expectation of Hospital Pharmacists on Risk Minimization Materials
Masahiro Hayashi, PhD
Toranomon Hospital, Japan
Pharmaceutical affairs specialist, Department of Pharmacy
Current Status and Future of Information Providing Materials for Risk Minimization
Asami Ezaki, MS
Pharmaceuticals and Medeical Devices Agency (PMDA), Japan
Division Director, PR Section, Office of Planning and Operations
Have an account?